Patent Issued For Humanetics’ BIO 300 Radiation Countermeasure Drug
In an announcement today, Humanetics Corporation reported that its BIO 300 medical radiation countermeasure drug candidate has been issued a U.S. patent. The patent is assigned to the United States of America with Humanetics as the designated licensee…
More: continued here
Filed under: Radiology on March 8th, 2010
You must be logged in to post a comment.